7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-N-[2-(4-morpholinyl)ethyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-imidazo[4,5-c]quinolin-2-amine | 1403491-56-4

• 英文名称: 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-N-[2-(4-morpholinyl)ethyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-imidazo[4,5-c]quinolin-2-amine
• 英文别名: 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-N-(2-morpholin-4-ylethyl)-1-(oxan-4-ylmethyl)imidazo[4,5-c]quinolin-2-amine
• CAS: 1403491-56-4
• 化学式: C₂₈H₃₆N₆O₄
• 分子量: 520.632
• InChiKey: XYYDBYHXTRBXDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  99.7
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  7-(3,5-dimethyl-4-isoxazolyl)-6-(methyloxy)-N⁴-(tetrahydro-2H-pyran-4-ylmethyl)-3,4-quinolinediamine 、 、 2-(4-呀啉代)乙基异硫代氰酸酯 以to give the title compound as beige solid (57 mg, 60%)的产率得到7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-N-[2-(4-morpholinyl)ethyl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-imidazo[4,5-c]quinolin-2-amine
  参考文献：
  名称：

  7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives

  摘要：

  小说喹啉化合物、含有这些化合物的制药组合物以及它们在治疗中的使用。

  公开号：

  US20140045834A1

文献信息

• 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives
  申请人：Demont Emmanuel Hubert

  公开号：US08846709B2

  公开（公告）日：2014-09-30

  Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.

  新型喹啉化合物药物组合物，以及这些化合物在治疗中的应用。
• 7-(3,5-DIMETHYL-4-ISOXAZOLYL)-8-(METHYLOXY)-1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES
  申请人：GlaxoSmithKline LLC

  公开号：EP2699573B1

  公开（公告）日：2017-05-31
• Compositions and Methods for Reactivating Latent Immunodeficiency Virus
  申请人：The J. David Gladstone Institutes

  公开号：US20150133434A1

  公开（公告）日：2015-05-14

  The present disclosure provides compositions and methods for reactivating latent immunodeficiency vims. The methods generally involve contacting an HIV-infected cell in which HIV is latent with an agent that binds a bromodomain (BRD) in the cell. Latently infected cells contain replication-competent integrated HIV-1 genomes that are blocked at the transcriptional level, resulting in the absence of viral protein expression. The present disclosure provides methods for reducing the reservoir of latent immunodeficiency virus in an individual.
• US8846709B2
  申请人：——

  公开号：US8846709B2

  公开（公告）日：2014-09-30